Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)

Authors:
  • RPR. Porta
    R. Porta
  • CQC. Queralt
    C. Queralt
  • FCF. Cardenal
    F. Cardenal
  • CMC. Mayo
    C. Mayo
  • MPM. Provencio
    M. Provencio
  • CCC. Camps
    C. Camps
  • DID. Isla
    D. Isla
  • JGJ. González-Larriba
    J. González-Larriba
  • MTM. Tarón
    M. Tarón
  • RRR. Rosell
    R. Rosell

Abstract
8038 Background: EGFR-mutant “oncogene-addicted” cancers are a distinct form of NSCLC that can be targeted with erlotinib (Paz-Ares et al. ASCO 2006). Methods: From April 2005 to December 2007, tumor biopsies from 2,312 stage IV NSCLC p from 43 centers were screened in one central laboratory in Badalona, Spain for EGFR exon 19 Δ746–750 deletion and exon 21 L858R mutation. Results were available within 8 days. p with EGFR mutations were selected for erlotinib therapy. Results: 307 p had EGFR mutations; data available on 165/307. 48 (29.1%) male; 112 (67.9%) never-smokers; 124 (75.2%) adenocarcinoma; 103 (62.8%) exon 19 deletion, 62 (37.6%) L858R mutation; 89 (53.9%) first-line, 76 (46.1%) second-line. Response in 111 p (73.1%); complete response in 20 p (13.2%); progressive disease in 16 p (10.5%). Odds ratio for response: 2.3 for p receiving first-line erlotinib and 2 for p with exon 19 deletion. Median survival: 24 months (m) overall; 27 m in responders vs 10 m in non-responders (P<0.001); not reached in...